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ABSTRACT
Background. It is unknownwhether changes in study sponsor-
shiphaveaffectedtheproportionofprospectiveresearchonsur-
gery, radiotherapy, and pharmacotherapy for head and neck
squamouscell carcinoma (HNSCC)beingpublishedover time.
Patients andMethods.Weexaminedprospective studies from
PubMed, Ovid MEDLINE, EMBASE, and the Cochrane Central
Register of Controlled Trials from1980, 1985, 1990, 1995, 2000,
2005, and 2010. Chi-squared tests were used to identify signifi-
cant associations between sponsorship and authorship, treat-
mentswithin studyprotocols, andpresentationof results,whereas
time-basedtrendswereanalyzedusingtheCochran-Armitagetest.
Results.Among 309 articles, industry (70, 22.7%) and theU.S.
government (65, 21%) were the most common sponsors.
There was a significant increase in the proportion of indus-
try-sponsored research (p for trend .013) and a decline in
U.S. government-sponsored research (p for trend  .001)
over time. The inclusion of surgery in treatment protocols
declined over the past four decades (p for trend  .003).
Protocols incorporating pharmacotherapy were more
likely to have industry support than those without pharma-
cotherapy (p .001), whereas protocols with radiotherapy
(p .003) or surgery (p .002) were less likely to have in-
dustry support.
Conclusion. Industry is the predominant sponsor of prospec-
tive HNSCC research, with an emphasis on pharmacotherapy.
TheOncologist2013;18:584–591
Implications for Practice: This article demonstrates the concurrent growth of industry funding and decline in U.S. government
funding forprospectiveheadandneckcancer research from1980to2010. Inaddition, thestudydemonstratesaclearassociation
between industry sponsorship and study of pharmacotherapy regimens, as well as a notable decrease in surgical research.
Changes in the sponsorship of head and neck cancer research may lead to fundamental changes in the types of therapies being
studied and the potential for financial and professional conflicts of interest. The U.S. government has an opportunity to ensure
that the future direction of head and neck cancer research reflects the public interest and should re-examine whether funding
policies and the Food and Drug Administration 510(k) clearance process may have had an indirect impact on the quantity and
quality of surgical and radiotherapeutic research.
INTRODUCTION
Head and neck cancer accounted for approximately 633,000
new diagnoses worldwide in 2008, over 90% of which were
squamous cell carcinomas (HNSCC) [1, 2]. Currently, surgery,
radiotherapy, and pharmacotherapy (including chemotherapy
and targeted therapies) constitute the primary modes of treat-
ment for HNSCC. However, there has been controversy among
physicians regarding optimal therapeutic regimens, particularly
foradvanced-stageHNSCC. Specific areasof controversy include
the significantly increased use of combined chemotherapy and
radiotherapy over the past two to three decades for definitive
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treatment of advanced tumors [3–6], stagnant or declining sur-
vival rates for certain types of head and neck cancer [4, 7], and
lack of high-quality evidence to guide HNSCC therapy, particu-
larlywithin thesurgical literature [3,5].Recentcommentaryalso
suggests that in contrast to the dearth of high-quality head and
neck surgical oncology evidence, there may be a comparative
preponderance of radiotherapy and chemotherapy literature,
and that policy-level changesmay be necessary to ensuremore
balanced research output that adequately considers the poten-
tial roleof each therapeuticmodality [3].
Publication trends may reflect both broader changes in
cancer research funding and shifts in research priorities by
funding sponsors. Industry has taken an increasingly promi-
nent role in supporting biomedical research, providing about
70% of the funding for all biomedical research in the United
States in 2008 [8, 9]. Jagsi et al. reported that oncology studies
that declared government funding outnumbered those that ac-
knowledged industry sponsorship by 50% versus 17% in 2006
[10]. However, detailed analyses of oncology clinical trials alone
have revealed that, with rare exceptions [11], industry sponsor-
ship is now predominant [12–14]. Recently, Sun et al. demon-
stratedtheimpactofbothindustryandgovernmentsponsorship
on randomized controlled trials (RCTs) for head andneck cancer
treatment from2000 to2010 [15]. It is conceivable that changes
instudysponsorshipovertimecouldinfluencepublicationtrends
in thebroaderheadandneck cancer literature.
Bibliometrics is a robust methodology that has been used
to estimate national and international support for oncology,
and thus can provide evidence to guide cancer control policy-
makingand research fundingpriorities [16]. The current study
is a comprehensive bibliometric analysis of prospective litera-
tureonHNSCCtherapy,examiningauthorship, studysponsor-
ship, treatment protocols, and the presentation of results
over a four-decade time frame.
MATERIALS ANDMETHODS
Four coauthors (G.H.S., J.J.H., N.M.M., andM.P.M.) systemat-
ically searched PubMed,OvidMEDLINE, EMBASE, and the Co-
chrane Central Register of Controlled Trials for potentially
qualifiedprospective literaturedescribingHNSCC therapeutic
regimens. The search strategy is described in the supplemen-
tal online data. Databases of conference proceedings and un-
published studies were not reviewed. We included articles
published in print during the years 1980, 1985, 1990, 1995,
2000, 2005, and 2010. Potentially qualified articles were then
collated into EndNote (Thomson Reuters, New York, NY,
http://thomsonreuters.com) and duplicate references were
removed.
Inclusion criteria included English-language articles on hu-
man subjects with mucosal HNSCC (involving the paranasal si-
nuses and sinonasal tract, nasopharynx, oral cavity, oropharynx,
hypopharynx,and/or larynx);prospectivestudydesign(e.g.,pro-
spective case series, pilot studies, clinical trials, comparative ef-
fectiveness studies, and randomized trials); and evaluation of
surgery, radiotherapy, pharmacotherapy (including chemo-
therapy and targeted therapies), “other” therapy (photody-
namic therapy, hyperthermia, viral therapy, and nutritional/
dietary therapy), and/or any combination thereof. For a study
toqualify as having includedagiven therapeuticmodality, the
article was required to mention in the Methods section that
the treatment was part of the formal protocol being tested.
Any cancer treatments completed prior to the study period
and reported in the participants’ clinical historywere not con-
sidered part of the active study protocol. Exclusion criteria in-
cluded the following: non-English language; animal studies;
basic science/experimental research, surveys, reviews, let-
ters, editorials, and any retrospective study design; prognos-
tic and diagnostic studies, cancer surveillance, and studies of
symptom alleviation; and articles in which mucosal HNSCC
was not the primary disease being studied.
We collected data on first and corresponding authors (sex
and nationality); journal impact factor (IF) based on the 2011
Journal Citation Reports (Thomson Reuters); inclusion of dis-
tant metastatic disease; RCT study design; inclusion of sur-
gery, radiotherapy, pharmacotherapy, and/or other therapy
in the treatment protocol; and presentation of results (posi-
tive results favoring experimental therapy, negative results
not favoring experimental therapy, or unclear). IF was strati-
fied into high-impact (IF  5) and low-impact (IF  5) sub-
groups to facilitate analysis.
The key outcome variable was study sponsorship, classified
into six categories: National Institutes of Health (NIH); non-NIH,
U.S. government (e.g., Department of Veterans Affairs); foreign
government; industry; philanthropic andnonprofit foundations;
and none or undeclared. For each government-based category,
sponsorship was defined as government-based funding and/or
grant support, or employment in a division of any national gov-
ernment. Industry sponsorship was defined as industry-based
fundingand/orgrantsupport,useof industry-provideddrugsup-
plies, employment in industry,honorariaorconsulting,orpartic-
ipation in a speakers’ bureau or advisory board. Philanthropic
and nonprofit sponsorship was defined as funding and/or
grant support fromprivate philanthropy or nonprofit founda-
tions,oremployment inaphilanthropicornonprofitorganiza-
tion, excluding any academic affiliations. Studies could have
more than one sponsor.
Because all variables in this study were categorical, chi-
squared tests were used to identify significant associations
with studysponsorship. Trends inauthorship, treatment type,
presentation of results, and sponsorship over time were ana-
lyzed using the Cochran-Armitage test. Statistical analyses
were performed using Stata 12.1 (StataCorp LP, College Sta-
tion,TX,http://www.stata.com).All statistical testsweretwo-
sided, and statistical significancewas defined as p .05.
RESULTS
We reviewed 1,165 articles, of which 309 qualified for analy-
sis. There was a steady increase in the total number of pro-
spective therapeutic studies of HNSCC over the study period,
from13 in1980 to70 in2010. Two-hundredsixty (84.1%)of all
309 first authors and 257 (84.6%) of all 305 corresponding au-
thorsweremale.Of35featuredcountries,theU.S.wasthemost
prolific countryoforigin forbothfirst (121outof309,39.2%)and
corresponding authors (119 out of 305, 39%), followed by Italy
(25authors)andGermany(22authors).NorthAmericaproduced
the highest number of first and corresponding authors (Fig. 1A,
1B). Therewere no statistically significant changes in first or cor-
responding authorship by sex or continent of origin over time.
However, a higher proportion of studies authored by women
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wereRCTs,asbothfirst (35.7%forwomenvs.23.5%formen,p
.039) andcorrespondingauthors (38.5%vs. 23.3%,p .011).
The number of RCTs ranged from 4 to 18 annually. There
were 51 RCTs analyzing pharmacotherapy, 49with radiother-
apy, 20 with surgery, and 3 with other therapies in the study
sample. There were 19 phase III clinical trials: 2 out of 41
(4.9%) studies in1980and1985, 4outof 93 (4.3%) in1990and
1995, and 14 out of 187 (7.5%) in 2000, 2005, and 2010. One-
hundred one (32.7%) publications studied distant metastatic
disease. Seventy-seven (24.9%) studies were published in
high-IF journals.
The largest sponsor of research in this study was industry
(70,22.7%), followedbyNIH(57,18.4%), foreigngovernments
(51, 16.5%), and philanthropic/nonprofit groups (34, 11%).
Even when we included support from U.S. governmental
sources outside NIH, the proportion of studies with govern-
mental funding (65, 21%) lagged behind industry. Thirty-six
(17.2%) studies were sponsored by oncology collaborative
groups, and 25 out of 36 (69.4%) were collaborative trials re-
ceiving primary National Cancer Institute (NCI) support. One-
hundred forty-nine (48.2%) studies lacked a study sponsor or
did not report a formal source of support. The yearly number
of studieswithagivensponsor isdepicted inFigure2.During the
1980–2010 time frame, there was a significant decline in U.S.
government-sponsored research as a proportion of all prospec-
tivestudies (p for trend .001)andanincrease in industry-spon-
sored research (p for trend .013).
The number and proportion of positive studies (232,
75.1%) across all years greatly exceeded negative studies (66,
21.4%) or studies with unclear results (11, 3.6%). There was a
Figure1. Categorizedbycontinentoforigin. (A)First authorship (n309). Studiesmayhavemore thanonesponsor. (B)Corresponding
authorship (n 305). Study protocolsmay includemore than one type of therapy.
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significant increase in the number of positive studies from
61.5% in1980 to82.9% in2010withadecline innegative stud-
ies from 23.1% to 17.1% (p for trend .002).
The therapeutic modalities we examined were repre-
sented as part of the therapeutic protocols of the studies in
our sample as follows, in decreasing order: pharmacotherapy
(247, 80%), radiotherapy (180, 58.3%), surgery (68, 22%), and
other therapy (13, 4.2%). The yearly percentage of studies
that included each therapy is depicted in Figure 3. Of these
modalities, only surgery demonstrated a significant decline
over time as a proportion of treatment protocols (p for
trend .003).Allother therapies retainedastablepresence in
the literature during the study time frame.
About 26.7% of studies that involved pharmacotherapy
declared industry support compared with 6.5% of those
that did not involve pharmacotherapy (p .001). Pharma-
cotherapy studies were published more frequently in
higher IF journals compared with studies without pharma-
cotherapy (27.9% vs. 12.9%, p  .014). Studies including
pharmacotherapy were significantly less likely to have un-
clear results compared with their nonpharmacotherapy
counterparts (2% vs. 9.7%, p  .014). Although they were
more likely to present both positive (76.1% vs. 71%) and
negative results (21.9% vs. 19.3%), neither of these rela-
tionships were statistically significant.
Studies that included radiotherapy as part of the thera-
peutic protocol were less likely to declare industry support
(16.7% vs. 31%, p .003). Studies with radiotherapy in the
protocol were more likely to be RCTs (36.7% vs. 11.6%, p
.001), but were published less frequently in higher IF jour-
nals (19.4% vs. 32.6%, p .009). There was no apparent as-
sociation with either positive or negative presentation of
results.
Studies that included surgery as part of the therapeutic
protocol were less likely to report industry support compared
with thosewithout surgery (8.8%vs. 26.6%,p .002). Studies
with surgery in the protocol were published less frequently in
higher IF journals (10.3% vs. 29.1%, p .002). As with radio-
therapy, studies featuring surgery had no association with
presentation of results. Studies with “other” therapeutic mo-
dalities were few in number and had no notable associations
to report.
Weconstructedamultivariate logistic regressionmodel to
explore potential factors in the predominance of pharmaco-
therapy in HNSCC research, including study sponsorship, con-
current inclusion of surgery, radiotherapy, andother therapy,
metastatic diseasewithin thepatient population, year of pub-
lication, and IF stratum(Table1). Research that includedphar-
macotherapy was again significantly associated with industry
sponsorship (p .004). The odds of surgical (p .001) and
other therapeutic interventions (p  .001) being present
within treatmentprotocols already containing chemotherapy
were both significantly lower.
DISCUSSION
In this large-scale bibliometric study of prospective HNSCC
therapeutic research, we identified a number of noteworthy
trends. First,weobservedanoverall increase in thenumberof
publicationsabout this fieldof cancer, but adecline in thepro-
portion of publications incorporating surgery as a component
of the treatment protocol. Second, we found an increase in
the proportion of studies supported by industry, a trend that
has been previously observed [12], as well as an association
between industry support and the inclusionofpharmacother-
apy in studyprotocols, suggesting that theavailability of fund-
ing may influence the distribution of therapeutic modalities
investigated in thepublished literature.Moreover,wenoteda
decline in the proportion of HNSCC studies sponsored by the
U.S. government.
Figure 2. Number of studies with a reported sponsor. Studiesmay havemore than one sponsor.
Abbreviation: NIH, National Institutes of Health.
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Three major issues related to these findings warrant dis-
cussion. First, the decline of both surgical research and U.S.
government-sponsored research may reflect ongoing global
research trends. A recent bibliometric analysis of 49,111 on-
cology articles determined that surgical research comprised
less than 9% of the sample, global cancer surgery research is
poorly cited relative toother aspects of oncology, andonly 5%
of annual global expenditures into cancer research are di-
rected toward surgery [17]. Study sponsorship trends are
more worrisome. The U.S. federal government has tradition-
ally been the largest government-based sponsor of biomedi-
cal research worldwide, but starting in the past decade,
private industryhasovertaken itas thepredominant sourceof
funding [9, 18]. For now, the majority of HNSCC randomized
trials are led by U.S. government sponsors [15], and the
growth of industry funding certainly benefits laboratories
strapped for fundingandcontinues toenergize the innovation
process. However,with increased industry funding, increased
industry input on research objectives and longstanding con-
cerns about financial conflict of interest and irregularities in
study conduct follow. This confluence of issues directly
poses a challenge for the core missions of NCI, and ongoing
U.S. federal budget concerns threaten toexacerbate this situa-
tion further. Researchers and policymakers urgently need to
strategize on how to, at the very least, maintain federal funding
toensurethat thedirectionofcancer researchreflects thepublic
interest.
Second, specific barriers may particularly affect surgeon-
scientistsattemptingtoconducthigh-quality research, includ-
ing modest surgical presence on NIH peer-review grant
committees, inconsistent biomedical research training, in-
creasing administrative burdens, and difficulties in overcom-
ing variousmethodological, ethical, and economic barriers to
conducting randomized trials and other high-quality surgical
research [17, 19–22]. Some authors have suggested that the
riseof translational research in the1990smayhave facilitated
the transference ofmolecular compounds from laboratory to
clinic, but not surgical translational work [23, 24]. The rela-
tively modest contribution by philanthropic and nonprofit
groups to HNSCC research and declining U.S. government in-
vestment might be a result of less vigorous advocacy by pa-
tient support groups. Greater public awareness of head and
neckcancermaybehelpful topromote increasedfunding,as it
has for breast cancer [25]. Stagnation in national budgets for
medical research is also pressuring researchers to pursue
commercialization of their scientific discoveries to remain fis-
cally solvent, a process that is conducive to drug and other
product-based research but not necessarily to research on
surgical procedures. It is alsopossible that resourcesarebeing
shifted away from surgery simply to address unmet research
needs in other treatmentmodalities.
Finally, the preponderance of pharmacotherapy trials rel-
ative to surgery and radiotherapy studies may relate to the
U.S. Food and Drug Administration (FDA) regulatory process.
Unlike drugs, certain medical devices (i.e., FDA class I and II
products) can circumvent full premarket assessment via the
510(k) clearanceprocess,whichallowsmanufacturers tomar-
ket devices if they are found to be substantially equivalent or
similar to either a previously 510(k)-cleareddevice or a device
approved prior to the passage of theMedical Device Amend-
ments of 1976. The 510(k) process does not require that the
manufacturer demonstrate safety, effectiveness, or innova-
tion [26]. Most radiotherapy delivery devices and surgical ro-
bots today fall into the class II category, which would
potentially qualify for the 510(k) process. Because 90% of
510(k) submissions for class I and II devices are ultimately ap-
proved [27], thebarriers tomarket entry using the510(k) pro-
cess are substantially less burdensome for manufacturers
Figure 3. Percentage of studies incorporating a given therapywithin study protocols. Study protocolsmay includemore than one type
of therapy.
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[26]. Consequently, there is less incentive for industry to fund
expensive clinical trials and other high-quality research for
surgery and radiotherapy devices when such research simply
maynotbenecessary forproduct clearance.Given that the In-
stitute of Medicine has now expressed concerns about the
510(k) process, it may be worth investigating whether imple-
mentation of this policy has contributed to a decline in both
surgical and radiotherapeutic research across all oncologic
subspecialties.
In today’s increasingly cost-conscious health care para-
digm, researchon innovative surgical techniquesandcompar-
ative effectiveness studies with other treatment modalities
are both more important than ever. Escalating health care
costs in cancer treatment are being driven by a variety of is-
sues: the sheer volume of oncologic surgical cases, the use of
promising but costly technologies in surgery such as robotics,
and the high costs of chemotherapeutic agents [17, 28]. Yet,
based on our findings, head and neck surgical researchers to-
day face withering support from both the U.S. government
and industry. Surgeons today are not only pursuing fewerNIH
grants as a group but also successfullywinning these grants in
significantly lower proportions [29], ultimately reducing the
overall impact of surgery on oncologic research discourse.
This is evident in our study in which there was a relative de-
crease in NIH sponsorship for studies involving surgical inter-
ventions, as well as an overall decline in U.S. government
sponsorship over time.
Furthermore, our study identified just five publications
with both industry funding and a surgical component in the 7
years analyzed, with no more than a single publication in any
given year. It has been theorized that industry invests in drugs
and not new surgical techniques because of differences in
commercial exploitability, and because pharmacologic re-
search is perceived tobemoreexciting bypopularmedia than
researchonsurgeryor radiotherapy [16]. Thismaybereflected
in part by the consistently high prevalence of pharmacotherapy
studies, alongwith their positive associationwith industry fund-
ing, in our study. Given that low research investment in cancer
maybe correlatedwithpoorer healthoutcomes [17], it is imper-
ative to reconsider policies that encourage insightful investiga-
tions inall aspectsofoncologic therapy.
Thereare several limitations to this study. First, as abiblio-
metric analysis, we evaluated only every fifth year for logisti-
cal reasons, exchanginga longer time frameof study for fewer
inclusive years. Because we were interested in long-term
trends, we did not consider this a detrimental issue. Our defi-
nition of study sponsorship was necessarily expansive to ac-
count for any potential noteworthy relationship between the
study sponsor and the authors. We note that our methods of
analyzing years of data at specific intervals and defining spon-
sorship have been published in previous bibliometric studies
[15, 30]. Aprior finding thatU.S. government-sponsoredhead
and neck cancer randomized trials was associated with posi-
tive reportingof results [15]wasnot replicated in thisanalysis,
whichwespeculate isbecauseof the inclusionofarticlesother
than RCTs and a longer time frame of study.We relied on dis-
closuresprovidedwithineacharticle,whichhavebeenknown
to be incomplete in the reporting of industry affiliations [31,
32]. We also acknowledge the possibility that, over time, the
rate of industry disclosures may have increased as a result of
greater investigator and editorial awareness of the influence
of industry sponsorship on research.
Next,wenotedthatevenafter limitingourstudysampleto
prospective research, nearly half of the studies did not list a
study sponsor or explicitly denied having external support. In
many cases, these projects may have been funded by the in-
vestigators or their institutions. Whether the lack of listed
funding sources in someof thesepapers is a result of failure to
report funding, conflict of interest, or other pertinent infor-
mation on the part of the authors or the journals remains un-
clear.Wedidnot contact correspondingauthorsor journals to
obtain missing information, so it is conceivable that the prev-
Table 1. Multivariate logistic regressionmodel of prospective
headandneck squamouscell carcinomaresearch that included
pharmacotherapy in the treatmentprotocol
Study characteristics Odds ratio (95%CI)
Industry sponsorship
Yes 6.2 (1.8–21.6)
No Reference
U.S. Government sponsorship
Yes 0.8 (0.4–2.0)
No Reference
Foreign government sponsorship
Yes 1.7 (0.6–4.8)
No Reference
Other sponsorship
Yes 0.3 (0.09–0.9)
No Reference
Surgery in treatment protocol
Yes 0.3 (0.1–0.6)
No Reference
Radiotherapy in treatment protocol
Yes 0.6 (0.3–1.2)
No Reference
Other therapy in treatment protocol
Yes 0.05 (0.01–0.2)
No Reference
Focus onmetastatic disease
Yes 2.3 (0.9–5.6)
No Reference
Year of publication
2010 0.2 (0.02–1.7)
2005 0.2 (0.02–2.0)
2000 0.2 (0.02–2.3)
1995 0.2 (0.02–2.2)
1990 0.3 (0.03–3.6)
1985 1.6 (0.1–23.2)
1980 Reference
Impact factor of publishing journal
High impact factor 1.6 (0.6–4.5)
Low impact factor Reference
Abbreviation: CI, confidence interval.
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alence of each type of study sponsor is higher than what was
observed herein.
Finally, we excluded all retrospective studies to focus pri-
marily on original articles that generally would be considered
“high-level” research within the evidence-based medicine
community. Surgery has long been dominated by retrospec-
tive research, particularly case series, and this is indirectly re-
flected in our analysis. Although prospectively designed
research is not guaranteed to be higher quality, there are
manyvalidprospectivestudydesigns,other thantheRCT, that
are suitable for answering surgical questions [33]. These
methodologies were not excluded in our analysis. Further-
more,prospectivestudies requiresignificantlymoreplanning,
coordination, and resources for primary data collection, and
theoretically would require at least nominal funding or sup-
port from external sponsors. Most retrospective studies, re-
views,andmeta-analysessimplyarenotasresource-intensive
as a long-term prospective study.
CONCLUSION
Though the U.S. government historically has been a prominent
sponsor of prospective HNSCC research, over the past four de-
cades, its involvementhasdeclinedprecipitously. Industry isnow
the predominant sponsor, primarily supporting studies with
pharmacotherapy in the treatment protocol. Of the primary
therapeuticmodalities,onlythepresenceofsurgeryhasdeclined
over time. Ensuring that sufficient high-quality prospective re-
searchexplorestheroleofsurgeryinHNSCCmanagementwillre-
quire long-term strategies to strengthen interest, training, and
funding in surgical research. Health care stakeholders should
carefully consider the ramificationsof industry fundingbeingthe
predominant influenceon the future of cancer research, aswell as
the potential impact of the FDA 510(k) clearance process on the
quantityandqualityofoncologicresearchinbothsurgeryandradio-
therapy.
ACKNOWLEDGMENTS
The authors thank Louise Davies, M.D., M.S., Rodney A. Hay-
ward, M.D., Jay F. Piccirillo, M.D., and Gregory T. Wolf, M.D.,
for advice on study design.
AUTHOR CONTRIBUTIONS
Conception and design: Gordon H. Sun, Jeffrey J. Houlton, Nicholas M. Moloci,
MarkP.MacEachern, Carol R. Bradford,MarkE. Prince,Reshma Jagsi
Provision of studymaterial or patients:GordonH. Sun,Mark P.MacEachern
Collection and/or assembly of data:Gordon H. Sun, Jeffrey J. Houlton, Nicho-
lasM.Moloci,Mark P.MacEachern
Data analysis and interpretation:GordonH. Sun
Manuscriptwriting:GordonH. Sun, Jeffrey J. Houlton, NicholasM.Moloci,Mark P.
MacEachern,CarolR.Bradford,MarkE.Prince,ReshmaJagsi
Final approval of manuscript: Gordon H. Sun, Jeffrey J. Houlton, Nicholas M.
Moloci, Mark P. MacEachern, Carol R. Bradford, Mark E. Prince, Reshma
Jagsi
DISCLOSURES
GordonH.Sun:RobertWood JohnsonFoundation (E),U.S.Department
ofVeteransAffairs, BlueCrossBlueShieldofMichiganFoundation (RF);
ReshmaJagsi:Eviti (C/A),AmericanCancer Society,National Institutes
ofHealth,National ComprehensiveCancerNetwork, BreastCancer
ResearchFoundation,AbbottPharmaceuticals (RF). Theotherauthors
indicatedno financial relationships.
Sectioneditors:Marshall Posner:GSK,Oxigene,Novartis, Eisai,GenMab (C/A);Acceleron (Phase II
trial) andAdler (Phase II trial) (RF); ThomasG.Roberts, Jr.: FarallonCapitalManagement LLC (E)
Reviewer “A”: Pfizer, Boehringer Ingelheim (H); Pfizer (RF)
(C/A)Consulting/advisory relationship; (RF)Research funding; (E) Employment; (H)Honoraria
received; (OI)Ownership interests; (IP) Intellectual property rights/inventor/patentholder; (SAB)
Scientific advisoryboard
REFERENCES
1.Ferlay J,ShinHR,BrayFetal.Estimatesofworld-
wide burden of cancer in 2008: GLOBOCAN 2008.
Int J Cancer 2010;127:2893–2917.
2.Marur S, Forastiere AA. Head and neck cancer:
Changing epidemiology, diagnosis, and treatment.
Mayo Clin Proc 2008;83:489–501.
3. Collins TR. Lecturer Warns Against Overuse of
CRT: Says Many Early-Stage Laryngeal Cancer Pa-
tients Overtreated. ENT Today. Available at
http://www.enttoday.org/details/article/1074133/
Lecturer_Warns_Against_Overuse_of_CRT_Says_
many_early-stage_laryngeal_cancer_pat.html. Ac-
cessed September 25, 2012.
4.HoffmanHT,PorterK,KarnellLHetal.Laryngealcan-
cer in theUnited States: Changes in demographics, pat-
ternsofcare,andsurvival.Laryngoscope2006;116:1–13.
5. Moyer JS, Wolf GT, Bradford CR. Current
thoughts on the role of chemotherapy and radia-
tion in advanced head and neck cancer. Curr Opin
Otolaryngol HeadNeck Surg 2004;12:82–87.
6. Shah JP, Karnell LH, HoffmanHT et al. Patterns of
care for cancerof the larynx in theUnitedStates.Arch
OtolaryngolHeadNeckSurg1997;123:475–483.
7. Kim L, King T, Agulnik M. Head and neck cancer:
Changing epidemiology and public health implications.
Oncology(WillistonPark)2010;24:915–919,924.
8. Bodenheimer T. Uneasy alliance—Clinical in-
vestigators and thepharmaceutical industry.NEngl
JMed 2000;342:1539–1544.
9.DorseyER,deRoulet J, Thompson JPetal. Fund-
ing of US biomedical research, 2003–2008. JAMA
2010;303:137–143.
10. Jagsi R, Sheets N, Jankovic A et al. Frequency,
nature, effects, and correlates of conflicts of inter-
est in published clinical cancer research. Cancer
2009;115:2783–2791.
11. Tuech JJ,Moutel G, Pessaux P et al. Disclosure
of competing financial interests and role of spon-
sors in phase III cancer trials. Eur J Cancer 2005;41:
2237–2240.
12.BoothCM,CesconDW,Wang Let al. Evolution
of the randomized controlled trial in oncology over
three decades. J Clin Oncol 2008;26:5458–5464.
13. Peppercorn J, Blood E, Winer E et al. Associa-
tionbetweenpharmaceutical involvementandout-
comes in breast cancer clinical trials. Cancer 2007;
109:1239–1246.
14. Rose SL, Krzyzanowska MK, Joffe S. Relation-
ships between authorship contributions and au-
thors’ industry financial ties among oncology
clinical trials. J Clin Oncol 2010;28:1316–1321.
15.SunGH,HoultonJJ,MaceachernMPetal.Influence
of study sponsorshiponheadandneck cancer random-
izedtrial results.HeadNeck2012[Epubaheadofprint].
16.SullivanR,EckhouseS, LewisonG.Usingbiblio-
metrics to informcancer researchpolicyandspend-
ing. In: Monitoring Financial Flows for Health
Research 2007. Geneva, Switzerland: Global Forum
for Health Research, 2008;67–78.
17. Purushotham AD, Lewison G, Sullivan R. The
state of research and development in global cancer
surgery. Ann Surg 2012;255:427–432.
18.MosesH3rd,DorseyER,MathesonDHetal. Fi-
nancial anatomy of biomedical research. JAMA
2005;294:1333–1342.
19. Bland KI. Concerning trends and outcomes for
National Institutes of Health funding of cancer re-
search. J Surg Oncol 2007;95:161–166.
20. Higgins KM, Wang JR. State of head and neck
surgical oncology research—A review and critical
appraisal of landmark studies. Head Neck 2008;30:
1636–1642.
21.HortonR. Surgical researchor comicopera:Ques-
tions,butfewanswers.Lancet1996;347:984–985.
22. Rangel SJ, Efron B, Moss RL. Recent trends in
National Institutes of Health funding of surgical re-
search. Ann Surg 2002;236:277–286; discussion
286–287.
23.CambrosioA,KeatingP,MercierSetal.Mapping
theemergenceanddevelopmentoftranslationalcan-
cer research. Eur JCancer2006;42:3140–3148.
24.LewisonG,PurushothamA,MasonMetal.Un-
derstanding the impact of public policy on cancer
research: A bibliometric approach. Eur J Cancer
2010;46:912–919.
25.Marshall JL. Philanthropy, advocacy and colon
cancer. Clin Colorectal Cancer 2011;10:290.
26. Committee on the Public Health Effectiveness of
theFDA510(k)ClearanceProcess, InstituteofMedicine.
MedicalDevicesandthePublic’sHealth:TheFDA510(k)
ClearanceProcessat35Years.Washington,DC:TheNa-
tionalAcademiesPress,2011.
27. GAO-09-190. Medical Devices: FDA Should
Take Steps to Ensure that High-Risk Device Types
Are Approved Through theMost Stringent Premar-
ket Review Process. Washington, DC: Government
Accountability Office, 2009.
590 Prospective Head andNeck Cancer Research
©AlphaMed Press 2013
CM
E
28.MeropolNJ, SchulmanKA. Cost of cancer care: Is-
suesandimplications. JClinOncol2007;25:180–186.
29.MannM, Tendulkar A, Birger N et al. National
Institutes of Health funding for surgical research.
Ann Surg 2008;247:217–221.
30. Jagsi R, Guancial EA, Worobey CC et al. The
“gender gap” in authorship of academicmedical lit-
erature—a35-year perspective. N Engl JMed2006;
355:281–287.
31. Angell M, Utiger RD, Wood AJ. Disclosure of
authors’ conflicts of interest: A follow-up. N Engl
JMed 2000;342:586–587.
32. Krimsky S, Rothenberg LS. Conflict of interest
policies in science and medical journals: Editorial
practices and author disclosures. Sci Eng Ethics
2001;7:205–218.
33. Slim K. Limits of evidence-based surgery.
World J Surg 2005;29:606–609.
See www.TheOncologist.com for supplemental material available online.
This article is available for continuingmedical education credit at CME.TheOncologist.com.
591Sun, Houlton,Moloci et al.
www.TheOncologist.com ©AlphaMed Press 2013
CM
E
